Background: The evidence for the comparative effectiveness and safety of ticagrelor versus clopidogrel in older patients with acute coronary syndrome (ACS) is limited, especially in the acute phase of ACS. This study aimed to compare the in-hospital outcomes of ticagrelor versus clopidogrel in older patients with ACS.
Methods: Hospitalised ACS patients aged ≥75 years who were recruited to the Improving Care for Cardiovascular Disease in China-ACS project between November 2014 and December 2019 and received aspirin and P2Y12 receptor inhibitors within 24 h after first medical contact were included. The primary outcomes were in-hospital major adverse cardiovascular events (MACE) and major bleeding. Multivariable Cox regression was performed to evaluate the comparative effectiveness and safety of ticagrelor and clopidogrel. Inverse probability of treatment weighting (IPTW) and propensity score matching analyses were performed to evaluate the robustness of the results.
Results: Of 18,244 ACS patients, 18.5% received ticagrelor. Multivariable-adjusted analysis revealed comparable risks of in-hospital MACE between patients receiving ticagrelor and clopidogrel (hazard ratio [HR] 1.12, 95% confidence interval [CI] 0.92-1.35). However, ticagrelor use was associated with 45% higher risk of in-hospital major bleeding compared with clopidogrel use (HR 1.45, 95% CI 1.09-1.91). Similar results were found in the IPTW analysis.
Conclusions: ACS patients aged ≥75 years receiving ticagrelor during the acute phase had similar risk of in-hospital MACE, but higher risk of in-hospital major bleeding compared with those receiving clopidogrel. More evidence is needed to guide the use of P2Y12 receptor inhibitors during hospitalisation in older patients with ACS.
Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02306616.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ageing/afac231 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Potent P2Y12 inhibitors versus clopidogrel in cancer patients undergoing percutaneous coronary intervention.
Can J Cardiol
March 2025
Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Background: Patients with cancer undergoing percutaneous coronary intervention (PCI) experience higher risk of both ischemic and bleeding events. The aim of this study is to assess ischemic and bleeding risks after PCI in cancer patients treated with potent P2Y12 inhibitors (P2Y12i; prasugrel and ticagrelor), compared to clopidogrel.
Methods: Consecutive cancer patients undergoing PCI at a tertiary centre between 2012 and 2022 and discharged on P2Y12i were included.
Ticagrelor Monotherapy Following Short-Term DAPT in ACS Undergoing PCI: A Systematic Review and Meta-Analysis.
Catheter Cardiovasc Interv
February 2025
University of Miami, Division of Cardiovascular Medicine, Miami, Florida, USA.
Background: Dual antiplatelet therapy (DAPT) for 1 year after acute coronary syndrome (ACS) in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES) is the standard of care. However, it is associated with a higher incidence of bleeding events. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to assess the safety and efficacy of short-term DAPT.
View Article and Find Full Text PDFTicagrelor Versus Clopidogrel in Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention for Acute Coronary Syndrome in Chronic Kidney Disease.
Am J Cardiol
February 2025
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio. Electronic address:
Objective This study aimed to compare the safety and efficacy of ticagrelor and clopidogrel in reducing major adverse cardiovascular events (MACE) among patients undergoing percutaneous coronary intervention (PCI) for chronic coronary disease. Additionally, secondary endpoints, including adverse events such as major bleeding, minor bleeding, and dyspnea, were assessed to evaluate the overall safety profile of both antiplatelet therapies. Methodology A prospective cohort study was conducted at Kuwait Teaching Hospital, Peshawar, Pakistan, enrolling 300 patients (150 receiving ticagrelor and 150 receiving clopidogrel) from July 2023 to June 2024.
View Article and Find Full Text PDFDe-escalating Dual Antiplatelet Therapy to Ticagrelor Monotherapy in Acute Coronary Syndrome : A Systemic Review and Individual Patient Data Meta-Analysis of Randomized Clinical Trials.
Ann Intern Med
February 2025
Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea (Y.-J.L., S.-H.L., S.-J.L., S.-J.H., C.-M.A., J.-S.K., B.-K.K., Y.-G.K., D.C., M.-K.H.).
Background: The role of transitioning from short dual antiplatelet therapy (DAPT) to potent P2Y12 inhibitor monotherapy in patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation remains inconclusive.
Purpose: To compare the effects of de-escalating DAPT to ticagrelor monotherapy versus standard DAPT from randomized clinical trials in patients with ACS.
Data Sources: PubMed, EMBASE, Scopus, and ClinicalTrials.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!